Analyst Ratings for [GH] Guardant Health, Inc.

1/23/25	Initiated	Overweight	X
GH Guardant Health Barclays
$60
6/28/24	Upgrades	Neutral Buy	X
GH Guardant Health Guggenheim
$36
6/3/24	Resumed	Buy	X
GH Guardant Health Jefferies
$32
4/24/24	Resumed	Buy	X
GH Guardant Health Craig Hallum
$28
12/14/23	Initiated	Neutral	X
GH Guardant Health Guggenheim
12/13/23	Initiated	Peer Perform	X
GH Guardant Health Wolfe Research
11/13/23	Upgrades	Mkt Perform Outperform	X
GH Guardant Health Raymond James
$27
9/28/23	Initiated	Outperform	X
GH Guardant Health Bernstein
$34
9/27/23	Upgrades	Neutral Overweight	X
GH Guardant Health Piper Sandler
$40
7/5/23	Resumed	Overweight	X
GH Guardant Health JP Morgan
$65
5/26/23	Upgrades	Neutral Buy	X
GH Guardant Health Citigroup
$28 $40
5/5/23	Initiated	Buy	X
GH Guardant Health UBS
$40
3/9/23	Downgrades	Buy Neutral	X
GH Guardant Health Citigroup
$60 $33
1/5/23	Initiated	Sector Outperform	X
GH Guardant Health Scotiabank
$36
11/1/22	Downgrades	Overweight Neutral	X
GH Guardant Health Piper Sandler
$65 $50
10/19/22	Initiated	Buy	X
GH Guardant Health Craig Hallum
$88
10/6/22	Initiated	Overweight	X
GH Guardant Health Stephens
$99
8/25/22	Initiated	Outperform	X
GH Guardant Health Credit Suisse
$80
6/3/22	Initiated	Overweight	X
GH Guardant Health Piper Sandler
$65
4/28/22	Resumed	Buy	X
GH Guardant Health BTIG Research
$135 $115
10/15/21	Resumed	Outperform	X
GH Guardant Health Cowen
$170
6/15/21	Initiated	Mkt Perform	X
GH Guardant Health Raymond James
6/3/21	Initiated	Buy	X
GH Guardant Health Goldman
$160
5/25/21	Initiated	Overweight	X
GH Guardant Health Wells Fargo
$145
1/11/21	Initiated	Buy	X
GH Guardant Health Stifel
$175
8/7/19	Reiterated	Buy	X
GH Guardant Health Canaccord Genuity
$96 $125
4/16/19	Initiated	Buy	X
GH Guardant Health Canaccord Genuity
$90
4/10/19	Upgrades	Neutral Buy	X
GH Guardant Health BofA/Merrill
$81 $84
2/28/19	Reiterated	Neutral	X
GH Guardant Health BofA/Merrill
$42 $60
10/29/18	Initiated	Neutral	X
GH Guardant Health BofA/Merrill
$37
10/29/18	Initiated	Overweight	X
GH Guardant Health JP Morgan
$42
10/29/18	Initiated	Outperform	X
GH Guardant Health William Blair

GH Guardant Health, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.